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INTRODUCTION FOR ANNUAL REPORT
With pride, I report that the Cancer Committee of
St. Luke’s Medical Center oversees a community oncology
program of great breath, depth, and human sensitivity a
program of which we should all be proud.
-

Marcia JS. Richards, M.D.
Chairperson of Cancer Committee

Marcia J.S. Richards, MD

As a teenager, my friends spent the sunny days of summer
baking in the sun to achieve a golden bronze cast, thought
to be physically appealing in those times. But today times
have changed, and pale is in. We now recognize
melanoma of the skin as the cancer rising most rapidly in
incidence in the United States. This is not good news,
however, public education and preventative measures can
decrease this burgeoning epidemic, if implemented. This
annual report focuses on melanoma and other skin
cancer, its diagnosis and treatment, as well as a summary
of 1994 cancer activity at St. Luke’s Medical Center.

A

1994 was a year of transition for the Cancer Program at
St. Luke’s Medical Center. Marija Bjegovich assumed the
role of Director of Cancer Services and disease site
programs in breast cancer and musculoskeletal tumors
were initiated with assigned coordinators. Stereotactic
breast biopsies became available in diagnostic radiology,
muhileaf collimators for treatment on the linear
accelerators in radiotherapy were installed for ease in
treatment customization, and the first Iodine-125 seed
implant was done for early prostate cancer at St. Luke’s.
The Cancer Committee members were active outside of
the usual meetings, facilitating the initiation of a primary
physician newsletter on screening, participating in the
American Cancer Society Making Strides Event,
presenting the Second Annual Schroeder Cancer
Conference, celebrating the hundredth Autologous Bone
Marrow Transplant patient, and funding research
programs through the Vince Lombardi Cancer Center
Research Advisory Committee.
Again the contributions and generosity of the green
coated Vince Lombardi Classic volunteers was
appreciated. Without their support many of the activities
that make our program special would not be possible. The
Vince Lombardi Golf Classic and Ball were again well
attended and well received benefit events.

Q uality assurance studies were done locally on combined
therapy for anal cancer, as well as participation in the
American College of Surgeon long and short term studies
on cancer of the larynx and hypopharynx.
With the advice of the Cancer Committee, a decision was
made on a new cancer registry software system that
would allow better customization of data entry, data
retrieval, and report generation.
1

SKiN CANCER EPIDEMIOLOGY AND TRENDS
-

James E. Ethington, MD
Dermatology

Cutaneous carcinoma is basically divided into two broad
groups: melanoma and non-melanoma skin cancer
(NMSC). NMSC includes predominantly squamous cell
and basal cell carcinoma, but also a panoply of other less
common tumors.
More than 1/3 of all cancer in the United States is nonmelanoma skin cancer. There are approximately
1,000,000 new cases per year, predominantly in
caucasians. Fortunately the mortality rate from basal cell
carcinoma is very low, with less than 1 in 10,000
metastasizing. Squamous cell carcinoma has a mortality
frequency of approximately 1,200 deaths per year in the
United States. The cumulative lifetime risk for nonmelanoma skin cancer is greater than 15%. In
approximately half of patients with NMSC a new tumor
will develop within 5 years. The highest incidence of basal
cell carcinoma in the United States is in Kauai, Hawaii,
with the annual incidence of 422 NMSC’s per 100,000
caucasians per year. Immunosuppressed patients, such as
organ transplants, have a 20-30% increased incidence of
squamous cell carcinoma.

of all skin carcinomas, melanoma currently displays the
most rapid incidence increase. Since 1973 the incidence rate
has increased at 4-6% a year. Projections suggest the
lifetime risk for melanoma development will be 1 in 75 for
individuals born in the year 2000. Presently there are
32,000 new melanornas annually (17,000 male and 15,000
female), of which one-fifth will end fatally. Malignant
melanoma is now the most common tumor for women ages
25-29. The increase in the mortality rate of melanoma is
second only to lung cancer.
The survival curve for melanoma relates in most cases
directly to Breslow’s depth, a pathological measurement
of tumor depth (see graph.) The survival curve
demonstrates the importance of early detection and
diagnosis of melanoma as the critical factor which
positively influences melanoma mortality. If the United
States is to decrease the mortality of melanoma (as in
Australia) greater emphasis on early detection is cardinal.
There is presently a trend toward diagnosis of early
curable thin melanomas and this must be continued
through public awareness, education, screening and early
removal of any suspicious lesions. The current S year
survival rate of 8 1 % reflects a vast improvement over the
49% rate in 1954.
2

For all types of cutaneous cancer there is an increased
incidence. Recent molecular studies have shown that
patients with basal cell carcinoma have subtle NA repair
defects similar to those more grossly seen in patients with
xeroderma pigmentosum. Molecular epidemiology, with
the study of DNA repair defects, P53 gene abnormalities,
and subtle chromosomal deletions as seen in familial
melanoma syndrome, may play major roles in future
detection of patients susceptible to skin cancer.
James E. Ethington, MD
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Kaplan-Meier survival curves for more than 5,000 patients. Patients are
stratified into groups based on lesion thickness: less than 0.76 mm
(squares); 0.76 to 1.5 mm (plus signs); 1.5 to 4 mm (diamonds); 4 or
greater (triangles). The curve for patients with lesions smaller than 0.76 mm
is corrected for referral bias; only patients referred before development of
recurrent or metastatic disease are included in this subset. (From Slingluff
CL Jr, Dodge RK, Stanley WE, et al. Cancer 1992;70:1924.)

CANCER INCIDENCE

SKIN
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INCIDENCE, CLINICAL CHARACTERISTICS, AND COMMON SITES OF PRINCIPAL CUTANEOUS CANCERS

Most common form of skin cancer;
occurs primarily in patients exposed to
prolonged or intense sunlight, especially
whites with light eyes, light hair, and fair
complexions.

BASAL CELL
CARCINOMA

COMMON SITES

CLINICAL CHARACTERISTICS

INCIDENCE

Nose, eyelids, cheeks and trunk.
Uncommon on palms and soles.
Metastases are extremely rare.

Nodiilo-ulcerative basal cell cancer:
Elevated lesions with umbihcated,
ulcerated centers; raised waxy or
“pearly” borders; moderately firm.
Superficial basal cell cancer: Barely
elevated plaques, usually with crusted and
erythematous centers and raised, threadlike pearly borders; often multiple.

I

SQUAMOUS
CELL
CARCINOMA

Less common than basal cell carcinoma;
occurs primarily on areas exposed to
actinic radiation and on vermilion
border of lips.

Appearance varies from an elevated
nodular mass to a punched-out
ulcerated lesion to a fungating mass.
Unlike basal cell carcinomas, squamous
cell carcinomas are opaque.

MALIGNANT
MELANOMA

Far less common than basal cell
carcinoma or squamous cell carcinoma.

Usually irregularly pigmented (black, gray,
white, blue, brown, red): usually more
than 6 mm in diameter and asymmetric.
May be flat or elevated, eroded or
ulcerated; outline usually irregular often
with notch; frequently mildly symptomatic
(e.g., pruritic). Characteristic clinical
features can be easily remembered by
thinking of ABCD:
A = Asymmetry
B = Border irregularity
C = Color Variegation
D = Diameter generally greater than 6 mm

75 percent occur on head, 15 percent on

hands, and 10 percent elsewhere. Can
metastasize to regional lymph nodes; in
more advanced lesions, visceral
(especially pulmonary) metastases can
occur.
Any cutaneous area, although the trunk
in men and the legs in women are
common, less common in areas
unexposed to sun; metastasizes, often
first to regional lymph nodes.

Reprinted with permission from the American Cancer Society, Wisconsin Division.
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According to present estimates from the National Cancer Institute, 40 to 50 percent of Americans who live to the age of 65 will have skin cancer at least once.
When reviewing the skin cancer cases at SLMC (melanoma has been excluded), 73% of the patients in 1989 and $1 % of the patients in 1994 were diagnosed
with skin cancer when they were 60 years of age or older.
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SURGICAL TREATMENT FOR NON-MELANOMA
SKiN CANCER

William P. LeFeber, MD
Dermatology

Skin cancer is the most common cancer in humans with
over 500,000 occurrences a year. The key with skin
cancer, as with any cancer, is early diagnosis since
treatment will be easier. We will deal only with basal and
squamous cell cancer (hereafter called “skin cancer”) in
this article, since melanoma is approached quite
differently.
Skin cancer, with the exception of melanoma, is basically
locally destructive and rarely metastasizes. Treatment is
usually local surgery, except in unusual situations (e.g.,
squamous cell cancer can metastasize in some settings).
These skin cancers must be taken seriously since they have
the potential to be destructive. If not cured, these cancers
can cause the loss of eyes, ears, or noses, and possibly
even death.
For most simple, small, clinically well defined skin cancers
a simple technique known as “electrodesiccation and
curettage” (ED and C) can be used. The procedure tends
to leave a scar the same size as the cancer. It should be
used only if a scar is acceptable, or in creases, where the
acceptable scar may not be as obvious. Local anesthesia is
used and the cancer is shaved off and sent to the
laboratory to confirm the diagnosis. Three additional
cycles of scraping the base with a curette and electro
desiccation of the base then follows. There is a hole left
where the cancer was and this will heal in the wound care.
This technique typically results in a 95% cure rate. If the
cancer recurs, it will do so at or in close proximity to the
site of the scar and then further treatment can be done.
For larger skin cancers or those in more cosmetically
conspicuous areas, excision with suture closure is usually
done. This is again done with local anesthesia after which
the cancer and some normal skin around it is cut out and
the hole, usually in a football shape, is sewn closed with
sutures. This specimen is sent to the laboratory for
diagnosis and to confirm complete removal. The resulting
scar is usually a thin white line. This technique also
typically has a 95% cure rate.
When skin cancer is in certain “danger areas” (discussed
later) or has recurred after previous treatment, then Mohs
Micrographic Surgery should be used. This technique was
developed by Dr. Fred Mohs in the 1930’s in Madison,
Wisconsin. It was originally called “Chemosurgery”
because layers of tumor were removed after in situ (on the
patient) fixation with zinc chloride paste. Gradually this
4

was replaced with the Fresh-Tissue technique which is
used today because it is quicker and less painful. The
Mohs technique is used all over the world now and is
considered the ultimate treatment for skin cancer because
it has the highest cure rate while preserving as much
normal tissue as possible. Mohs is performed mostly by
dermatologists, but other surgical specialties are beginning
to appreciate the usefulness of the technique.
The technique is actually very logical. It is an office-based
procedure utilizing local anesthesia. First, the obvious
tumor is removed, or “debulked” in a “saucerized”
manner (Step 1 in the figure). Then a thin layer of tissue is
removed around the defect andbelow the base so that a
bowl-shaped piece of tissue is removed. This bowl of
tissue is cut into pieces so that the entire surface can be
laid flat. A map is made of the pieces with dyes used to
mark the pieces so that it is clear how they are oriented to
each other (e.g., 6 pieces in Step 2 in the figure). Frozen
sections are made and the entire surface is checked under
the microscope. This way any small extension of tumor
that goes beyond the layer just removed will be seen and
marked on the map (colored in on figure) and the surgeon
will know where to excise another layer (Step 3 in the
figure with two areas excised and cut into 4 pieces). This
second layer may show residual tumor and another layer
(or “stage”) will be removed until no residual tumor is
seen, or a “tumor free plane” is achieved (Step 4 in the
figure). It should be clear that this technique will most
effectively remove the tumor while preserving as much
normal tissue as possible.
There will be a defect left that may be allowed to heal on
its own, by “secondary intention.” However, usually the
defect is sutured closed either primarily (in a line) or by
using flaps (moving skin from next to the defect) or grafts
(transplanting skin from another area). This simplifies the
wound care and usually results in a better cosmetic and
functional result. Most Mohs surgeons perform their own
repairs, but we may have a plastic surgeon help with more
complex repairs.
Schematic depiction of Mohs micrographic surgery.
1) All visible tumor is removed first.

I
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2) Map of first layer with tumor.

3) Map of second layer with tumor.

...

..

(I)

....

4)

Map of third layer tumor free.

Mohs surgery is usually used for basal cell or squamous
cell cancer since these tumors have a contiguous growth
pattern and rarely metastasize. Use in melanoma is being
studied, but it is still controversial since melanoma
extensions of tumor are not always contiguous with the
primary tumor. Mohs should not be used for all basal and
squamous cell cancers since it is time consuming and
expensive. It should be considered for situations where
these cancers are particularly aggressive and high
recurrence rates are seen. Examples would be: cancers
located in the embryonic fusion planes (ears, temples,
eyelids, nose and upper lip), recurrent cancers, clinically
poorly defined cancers, histologically aggressive cancers
(e.g., infiltrative, morpheaform or metatypical basal cell
or very atypical squamous cell cancers), locations where
tissue preservation is important (e.g., nose or eyelid), or

incompletely excised cancers. Mohs surgery usually results
in 96-99% cure rates, even with these difficult cancers.
Other treatment modalities can result in 50-70% cure
rates in these difficult situations, which can be
unacceptably low.
This briefly summarizes surgical treatment of skin cancer
including the Mohs Micrographic surgery technique and
where and why to use it. Although basic surgical
approaches can be used for most small, simple, previously
untreated basal and squamous cell cancers, Mohs surgery
is a wonderful technique for the difficult skin cancer.
A

William P. LeFeber, MD

SLMC FIRST COURSE TREATMENT FOR SKIN CANCER (MELANONA EXCLUDED)
NUMBER OF CASES

Non cancer directed surgery

NUMBER OF CASES

i22i

TREATMENT
5

2
14

Radiation only
Local tumor destruction w/o path. specimen

0

Simple excision/excsn. bxl wedge resection/laser surgery with path. specimen

34

162

Simple excision/excsn. bx/ wedge resection/laser surgery with path. specimen and rad.

2

11

Simple excision/excsn. bx/ wedge resection/laser surgery with path. specimen and chemo

0

Shave/punch biopsy, not a wide excision

2

Radical excision w/o lymph node dissection

57

Radical excision w/o lymph node dissection, with rad.

5

Radical excision with lymph node dissection

4

0

Radical excision with lymph node dissection, with BRM, chemo and hormones

0

0

Surgery of regional and/or distant site(s)/node(s) only

1

0

119

192

Radical excision with lymph node dissection, with rad.

When reviewing the treatment of skin cancer at SLMC for non-melanoma malignancies, we note a significant decrease in the volume of radical surgical
treatments performed in 1994 when compared to 1989. This could possibly be due to better surveillance techniques and earlier stage at diagnosis which
results in less radical surgical procedures.
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RECONSTRUCTIVE SURGERY FOLLOWING SKIN CANCER

Paul W. Loewenstein, MD
Plastic Surgery

Basal cell carcinoma is the most common and least
aggressive of the three major types of skin cancer.
However, advanced cases continue to present to the
plastic surgeon in spite of the greater public education
efforts by the medical community. The size, shape and
location of the surgical defect following excision will
determine which method of closure is indicated. The
simplest, and frequently best method, is direct closure. If
this in not possible, then a skin graft or local flap will be
necessary. Skin grafts to the face generally are taken from
the “blush” area above the clavicles. An understanding of
geometric principles and familiarity with the relaxed skin
tension lines is necessary for achieving good results with
local flaps. Figure 1 shows a surgical defect following the
excision of a basal cell carcinoma with possible local flaps
outlined in surgical ink. Figure 2 shows the results six
months later with a nice restitution of the normal
nasolabial fold.

A

L

A

Figure 1

Three-dimensional defects of the nose, lips and ears are
more challenging and usually require distant flaps for
reconstruction. For the nose, the surgeon must supply
lining, support and skin coverage to reconstruct a fullthickness defect. These procedures often need to be done
in stages to achieve the end result. An example of a fullthickness defect of the left side of a woman’s nose is
shown in Figure 3, following excision by the Mohs
technique. This was a twice recurrent basal cell
carcinoma that had also been irradiated in the past.
Figure 4 shows the patient following reconstruction using
intranasal tissue for lining, septal cartilage for support
and a forehead flap for external coverage. Several stages
were necessary to achieve this result.

Figure 2

For the lip, we must not only “dose the hole,” but also
ensure good muscular function and control for speaking
and eating. Figure 5 shows a patient with a neglected
basal cell carcinoma of the upper lip. Figure 6 shows the
intraoperative defect and Figure 7 shows the patient
postoperatively, illustrating good muscular function
following myocutaneous flap reconstruction.
Surgical treatment of melanoma has undergone significant
change over the last 15 years. An excellent review article
on current therapy for cutaneous melanoma appeared in a
recent Journal of the American Academy of Dermatology.
Although specific recommendations for surgical margins
vary from one institution to the next, we can say without
a doubt that no patient need undergo excision wider than
6

w1
Figure 3

3 centimeters. Clearly the most important prognostic
factor in melanoma is tumor thickness as described by
Breslow. Surgical margin resection is based on the
Breslow thickness of the primary tumor. My current
practice is to excise a Breslow thickness 1 mm or less
tumor with a 1 cm margin. For 1-2 mm thick melanoma,
we use a 2 cm margin, unless doing so would mean
sacrifice of a vital structure. In that case, a narrower
margin may be carried out. For a tumor greater than
2 mm in thickness, a 2-3 cm margin is carried out. It is
generally agreed that the depth of the resection should be
to the fascia.

Figure 5

Recent advances in the field of intraoperative lymph node
mapping and sentinel node biopsy will probably allow
surgeons to better select patients who should undergo
prophylactic lymph node dissection. This primarily
involves head and neck melanomas, since the World
Health Organization study shows that extremity
melanoma can be treated expectantly with regard to
regional lymph node dissection. For head and neck
tumors, preliminary reports indicate a very high reliability
of sentinel node biopsy in predicting which patients will
have positive lymph nodes.

A

Figure 6

Paul W. Loewenstein, MD

‘1

c’

Figure 7

Figure 4
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PAThOLOGY OF SKiN CANCER
width and estimate risk of metastases based on the
thickness of the melanoma.
James L. Troy, MD
Dermatopathology

7c

Biopsies of skin cancers define the precise type of cancer
and provide information to help choose the optimal
treatment for the patient.
The most common skin cancer is basal cell carcinoma.
Margins of excisions can be assessed to be sure that the
tumor has been totally removed. In some instances,
especially in those tumors with thickening of collagen
forming a morpheaform pattern, cure rates are higher
using special surgical interventions such as Mohs
micrographic surgery.
Margins of surgical excisions of squamous cell carcinoma
can also be evaluated. On certain anatomic locations,
such as the ear or lower lip, squamous cell carcinomas
may be more likely to metastasize, and patients may
require closer monitoring. Verrucous squamous cell
carcinomas may have coincident changes of papilloma
virus infection, and the option of radiation therapy is
usually not chosen.
Malignant melanoma is the least frequent but most
dangerous skin cancer, and early detection and complete
removal are critical. Clinicians choose surgical margin

The Clark’s level of a melanoma is an estimate by the
pathologist of the depth of extension (i.e., thickness)
defined by nearby structures of the skin. A level II
melanoma extends into, but does not fill the papillary
dermis; a level III melanoma fills the papillary dermis; a
level IV melanoma extends through the papillary dermis
and into the reticular dermis; and a level V melanoma
extends even deeper, into fat. Because the skin layers may
differ in thickness at various body sites, and because in
some instances those layers can expand or be difficult to
recognize, the Clark’s level is usvially supplemented by a
ruled measurement.
Using an ocular micrometer, the pathologist can measure
the thickness of melanoma directly. The convention,
called the Breslow measurement, is to record the exact
millimeter depth of melanoma measured from the
granular cell layer of the epidermis downward to the
deepest and last definite cell of melanoma. From this
quantitative measurement, the patient’s risk for
metastases is best assessed, and a choice for surgical
margin width is made.
Close collaboration between clinician and pathologist is
critical in designing optimal therapy for all types of skin
cancer. Detailed reports by the pathologist and direct
consultation with the clinician result in specific and
sophisticated recommendations for care.
James L. Troy, MD

6 MOST COMMON SKIN CANCERS AT SLMC
1989

-

HISTOLOGIES

Basal Cell Carcinoma
Squamous Cell Carcinoma
Malignant Melanoma
Bowen’s Disease
Kaposi’s Sarcoma
Malignant Lymphoma
10 others with counts not shown

-

A COMPARISON OF 1989 AND 1994
1989

NUMBER OF CASES

56.7%

76
26
11
3
3
3
12
I 34

— 8.2%
12.2%
12.2%
12.2%

0
1994

-

HISTOLOGIES

Basal Cell Carcinoma
Squamous Cell Carcinoma
Squamous Cell Carcinoma, In Situ
Malignant Melanoma
Basosquamous Carcinoma
Superficial Spreading Melanoma
12 others with counts not shown

19.4%

5

10 15 20 25 30 35 40 45 50 55 60 65 70
1994

NUMBER OF CASES

119

55.1%

35
15
15
6
6
20
216

— 6.9%

16.2%

6.9%
12.8%
12.8%

0

5

10 15 20 25 30 35 40 45 50 55 60 65 70
PERCENT OF CASES

According to “The Diagnosis and Management of Common Skin Cancers,” an American Cancer Society professional education publication: More
cancers occur on the skin than at any other anatomic site. Because they are directly visible and easily accessible, they offer a unique opportunity for early
diagnosis, treatment and cure. Basal cell carcinoma (BCC), squamous cell carcinoma (5CC), and malignant melanoma are the 3 most common cutaneous
cancers and account for the greatest majority of all primary malignant tumors of the skin. This is also reflected at SLMC where the 3 most common
types of skin cancer in both 1989 and 1994 are BCC, 5CC, and melanoma.
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RADIATION THERAPY FOR SKIN CANCER

Iames E. Bruckman, MD
Radiation Oncology

Skin cancer represents a paradigm in cancer management.
Significant information is available on prevention. There is
appropriate, effective screening, and there are a number of
effective and relatively inexpensive treatment methods, one
of which is radiation.
Historically, in the 1920’s 1930’s, the only radiation
therapy equipment available produced low energy x-rays
that deposited energy in superficial tissue and would not
penetrate deeply into underlying tissues. This was ideal for
skin cancer where the treatment volume is superficial and
the normal tissue to avoid is deeper. Thus, skin cancers were
one of the first to be treated by radiation therapy. Today the
modern version of this equipment from the 1920’s and
1930’s (orthovoltage and contact radiation units) is the
mainstay in treatment.

The place of radiation therapy in the treatment of
melanoma is different than the other types of skin cancer.
Radiation therapy is not used in the treatment of the
primary lesion. Radiation therapy is sometimes used as
adjuvant treatment of metastatic lymph node sites after
lymph node dissection, but is most often used for palliation
of symptomatic distant metastatic sites. These include brain
metastases, bone metastases, and spinal cord compression,
where radiation therapy can offer symptomatic
improvement in up to 80 percent of cases.
Radiation therapy is also often useful in less common skin
cancers, such as epidemic and classic types of Kaposi’s
sarcoma, keratoacanthoma, mycosis fungoides, lymphoma
cutis, and Merkel cell carcinoma.

-

J ames E. Bruckman, MD

:‘7;
‘

With over half a million new cases per year, skin cancers are
the most common type of cancer. Fortunately, most can be
diagnosed early and treated effectively. The most common
histologic varieties of skin cancer, basal cell carcinoma and
squamous cell carcinoma, are cured in at least 95 percent of
cases with either surgical therapy or radiation therapy. Since
simple excision is effective, inexpensive, and easy, it is the
preferred method of treatment.
.

Certain tumor characteristics, tumor locations, or patient
limitations are more difficult to handle by surgery and are
ideally treated with radiation therapy. Examples of these
include: large tumors (see Figure 1 ), those with indistinct
borders, superficially spreading or multicentric tumors, and
tumors growing in difficult to operate areas, i.e., around the
nose, eyelids, and pinna. Radiation therapy is often used in
cases of incomplete resection, positive margins, recurrent
tumor, or in patients not considered operable for medical
reasons.
The technique of radiation therapy involves shaping the
radiation beam to conform to the desired treatment volume
by individually constructed lead shielding, usually giving
three to twenty treatments over one to four weeks. The
treatment will cause an erythematous to desquamative skin
reaction with skin healing in three to six weeks. Often there
are long-term mild effects of skin atrophy, dryness, or
depigmentation. Overall, the cosmetic result is usually
excellent, which is one of the advantages of radiation
therapy. (See Figure 2.)

,

Figure 1
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Figure 2
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MELANOMA: FINIJING II EARLY IS STILL THE BEST
TREATMENT

Jonathan S. Treisman, MD
Hematology/Oncology

Melanoma is a skin cancer of the melanocytes, or pigment
producing cells of the body. It most often originates in the
skin, usually in a nevus (mole) or less commonly in the
eye. Melanoma can be a very frustrating disease to both
physicians and patients because of its resistance to the
commonly used anticancer agents and radiation, and
because of its history of recurring even many years after
surgical removal. In addition, the incidence of the disease
has been steadily rising over several decades, affecting
both young and old adults. Despite this, melanoma has
shown us that we can improve treatment through science
and education. It has taught us a great deal about the
biology of cancer and the immune response of the body to
cancer.
It makes sense that catching cancer early would be
helpful, and for melanoma this is especially true.
Melanoma usually grows locally on the skin where it can
be seen before it spreads. It starts as a nevus which is a
readily identifiable lesion. There is usually an orderly
progression, first penetrating the deep layers of the skin,
becoming progressively thicker, then traveling to the
lymph nodes and traveling through the blood stream to
distant sites. Melanoma is unusual in that the cells know
no bounds, and can form new growths or metastases in
virtually any organ. The best tip that a melanoma is
forming is that a nevus begins to change. The changes can
best be remembered as the A,B,C and D’s of melanomas.
These are Asymmetry or unevenness, Border becoming
irregular, Color that is changing, variegated or very dark,
and Diameter that is greater that 0.6 cm (a pencil eraser).
Moles that change need to be checked and usually
removed. People with multiple moles or irregular moles
must also be evaluated regularly for progression to frank
melanoma. The key to melanoma cure has been to detect
them and perform surgery early, when the lesions are
small. The thickness of a melanoma is a predictor for
recurrence, with tumors over 1.5 mm thick being
especially likely to metastasize.
Once melanoma has spread it is generally incurable, with
a median survival of six months. In addition, those
melanomas that have already spread to the lymph nodes
are especially likely to recur. This has led to a large effort
to prevent recurrences in those patients who are at high
risk. A large number of modalities have been tried
including chemotherapy and radiation. However, the best
results have come from studies of stimulation of the
10

body’s immune system. One form of stimulation has been
through vaccines made using melanoma cells, the best
known of these being Melacine. Controlled studies of this
agent are ongoing, but early studies suggested it could
decrease the odds of melanoma recurrence. Another form
of stimulation is using Interferon, a substance the human
body secretes in response to viral invasion. Controlled
studies have recently shown that this agent can reduce the
risk of recurrence in patients who have tumors over 1.5
mm or lymph node spread. Patients at St. Luke’s Medical
Center with these high risk tumors are now being treated
with Interferon-a2b therapy.
Unfortunately, some patients fiid the melanoma after is
has already spread, or their disease recurs following
treatment. Generally, the goal of treating such melanomas
has been to decrease or palliate the symptoms of the
disease. Chemotherapy can effectively reduce the size of
some melanomas but is not curative and the duration of
responses are usually very short.
A clue to an alternative way to treat melanoma came from
the sudden, unexplained disappearance of some patient’s
tumors. This suggested that a person’s body has the
capacity to recognize the tumor as being abnormal, and
eliminate it. A breakthrough to using this system came
from work by Dr. Steven Rosenberg. He found that giving
patients large amounts of the agent Interleukin-2, which
has the effect of stimulating the lymphocytes, or white
blood cells, could cause some of the tumors to shrink
away. Better yet, many of them stayed away.
Today at St. Luke’s Medical Center we continue to
expand on the use of the immune system to treat
melanoma. We have protocols in place to treat patients
with Interleukin-2, usually in combination with
chemotherapy. In addition, protocols which use
lymphocytes obtained from the tumor, Tumor Infiltrating
Lymphocytes (TIL), are now being used to further
specifically attack the tumor. It is through these studies
that the potential for the body’s own immune system to
reject the tumor can be studied and enhanced. Research is
ongoing for ways to genetically modify the cells used for
treatment so that they are more effective in the treatment
of disease. In addition, through an understanding of the
characteristics of melanoma, on a molecular level, new
vaccines are being developed as a possible means of
eliminating melanoma.
Although there are many breakthroughs in sight or in the
making, for now the best treatment is to find the
melanoma early and have it removed.

J onathan S. Treisman, MD

MELANOMA ITS DEVELOPMENT
-

LIFETIME RISK OF AN AMERICAN DEVELOPING
INVASIVE MELANOMA

DANGER SIGNALS SUGGESTIVE OF MALIGNANT
TRANSFORMATION IN PIGMENTED LESIONS
Change in Color:
Especially sudden darkening, mottled and variegated shades of tan,
brown, and black; red, white, and blue
Change in Diameter:
Especially sudden increase
Change in Outline:
Especially development of irregular margins
Change in Surface Characteristics:
Especially scaliness, erosion, oozing, crustiig, bleeding, ulceration,
development of a mushrooming mass on the surface of the lesion
Change in Consistency:
Especially softening or friability
Change in Symptomatology:
Especially a sense of pruritus
Change in Shape:
Especially irregular elevation from a previously flat condition
Change in the Surrounding Skin:
Especially “leaking” of pigment from lesion into surrounding skin or
pigmented “satellite” lesions

1935

1960

1980

1985

1992

2000 (Projected)

According to CA A Cancer Journal For Clinicians: Melanoma rates are
rising faster than any other cancer in men, and second only to lung
cancer in women. Melanoma is currently the 8th most prevalent cancer
in the U.S. If the 4-6% annual increase in melanomas continues, the
American lifetime risk of developing Melanoma will reach 1 in 75 by the
year 2000.

Reprinted with permission from the American Cancer Society,
Wisconsin Division.

—

SLMC MELANOMA GENERAL SUMMARY
STAGE AT DIAGNOSIS 1989 VS 1994
-

Although sunlight has been implicated in the development of malignant
melanoma, its etiology is less certain than that of other skin cancers. The
relation of benign melanocytic nevi to malignant melanomas is also
uncertain. However, any pigmented lesion that changes color, diameter,
outline surface characteristics, consistancy, or shape; demonstrates
change in the surrounding skin; or is symptomatic (tender, pruritic,
infected, or bleeding) must be viewed with suspicion, and an appropriate
biopsy should be performed.

90%

SKIN MELANOMA AT SLMC
1989

1994

(No. of Cases)

(No. of Cases)

Malignant Melanoma

Ii

is

Superficial
Spreading Melanoma

2

6

Melanoma In Situ

1

2

Nodular Melanoma

1

1

TOTAL

15

24

.

Histology

1989 1994 1989 1994 1989 1994 1989 1994 1989 1994
In Situ
Local
Regional
Distant
Unknown
STAGE AT DIAGNOSIS

Regular screening and self exams can detect melanoma at an early stage,
when treatment is more likely to be successful. The graph shows a
comparison between 1989 and 1994 SLMC melanoma cases and those
for the state of Wisconsin ( I 993 case figures were the most recent
available). The comparison shows a lower percentage of patients
diagnosed with in situ disease at SLMC, but a higher percentage of
patients diagnosed with local disease. According to SEER, approximately
82% of melanoma cases are diagnosed with local disease. This number is
higher than that reflected for both SI.MC and the state of Wisconsin.
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MELANOMA Al SLMC A STATISTICAL REVIEW
-
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Evidence has shown that sun exposure promotes malignant melanoma. People working indoors but participating in sporadic outdoor recreation are at
greatest risk. By contrast, an outdoor worker subjected to chronic sun exposure is more likely to develop either basal cell or squamous cell carcinoma.
According to the American Cancer Society, the most common sites of melanomas are on the upper back in men and on the legs in women. These are
areas easily reviewed during a complete physical exam, which can facilitate early diagnosis and treatment. A review of melanoma patients at SLMC
(presented above) did not show the same tendency, but rather a higher number of cases affecting the upper arms and shoulders than any other locations.

MELANOMA OF THE SKIN, 1989 VS 1994 AGE AT DIAGNOSIS BY SEX
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According to “Prevention and Early Detection of Malignant Melanoma,” an American Cancer Society pamphlet: In the U.S., melanoma rates are
increasing in all age groups, but the greatest rate of increase is in men, particularly among men over 65. Before age 40, melanoma occurs in women more
frequently than in men. However, at the older ages, the rate is higher among men. Although it is one of the more common cancers diagnosed among
young adults, 75% of the cases occur after age 40. At St. Luke’s Medical Center, we have noticed an increase in the number of female melanoma
patients under the age of 40 since 1989. When reviewing SLMC melanoma cases, we see that 86% of the patients diagnosed with melanoma in 1989 and
70% of the patients diagnosed with melanoma in 1994 were over age 40. There has also been a change in the ratio of male to female cases at St. Luke’s.
Whereas, in 1989 the ratio was 2:1, in 1994 the ratio became 1:1. While melanoma is on the rise, it has not increased at the same rate in men and
women. Unlike the expectations by the American Cancer Society, St. Luke’s volumes suggest a higher rate of female melanoma cases when compared to
S years ago.
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SURGICAL TREATMENT OF CUTANEOUS MELANOMA

James L. Mahoney, MD
General Surgery

I
I
Surgical excision is the main therapy that is utilized for
cutaneous melanoma and it is often utilized to treat
regional lymph node metastasis. In addition, surgical
resection can be performed in some symptomatic patients
with isolated distant metastases. Appropriate surgical
treatment of cutaneous melanoma is a controversial topic
with most of the controversy surrounding the use of
elective regional lymph node dissection.
(

-

The severity of cutaneous melanoma in any given patient is
based upon the thickness of the tumor and this same
measurement is used to determine the necessary surgical
therapy. The margin of normal skin that is excised around
a primary lesion is based upon the thickness of the
melanoma. Margins of 1, 2, or 3 cm are usually recom
mended and it has been shown that a margin of greater
than 3 cm is unnecessary even for very thick primary
lesions. Skin graft into the sight of excision may be required
but is not used as frequently now that excisions of the
primary melanoma have become more conservative.

sites being either the cervical, axillary or inguinal lymph
nodes. Most authors agree that regional lymph node
dissection should be performed in patients with clinically
enlarged lymph nodes that are present in the drainage
basin of a primary melanoma. This approach may prevent
further metastases of the melanoma and improves the
local disease control. Removal of regional lymph nodes
that are not enlarged is termed elective lymph node
dissection and it is probably the most controversial area
in melanoma surgery. The decision to perform an elective
lymph node dissection is based upon the risk of
metastases from the primary tumor to the regional lymph
nodes. This risk is based upon factors such as the tumor
thickness and anatomic location 6f the primary tumor,
the presence or absence of tumor ulceration and patient’s
sex and age. Long term morbidity following elective
lymph node dissection can be minimized with proper
surgical judgement and technique.
Surgical intervention is rarely indicated in patients with
widespread metastatic disease from melanoma; however,
there are exceptions. Patients with intra-abdominal
metastases may present with complications such as
bleeding or obstruction and in selected cases, resection
may prolong life and improve the patient’s quality of life.
Melanoma remains a challenging disease and new
modalities of treatment continue to be explored for those
patients who are not cured by surgical excision.
James L. Mahoney, MD

The initial sight of metastases from a primary melanoma
is to the regional lymph nodes, with the most common
SLMC FIRST COURSE TREATMENT FOR MELANOMA
TREATMENT
Non cancer directed surgery

NUMBER OF CASES
1989

NUMBER OF CASES
1994
0

Bioresponse Modifier and Chemotherapy
11

Simple excision/excsn. bxl wedge resection/laser surgery with path. specimen
Radical excision w/o lymph node dissection

11

3

2

5

0

1

Radical excision w/o lymph node dissection, with BRM
Radical excision with lymph node dissection
Radical excision with lymph node dissection, with BRM
Radical excision with lymph node dissection, with BRM, Chemo and Hormones
Surgery, NOS

1
15

24

Early recognition and excision of primary cutaneous melanoma is the best method to assure a favorable outcome. There are four methods of treatment
used: 1) surgery, which is used in 90% of cases, 2) radiation therapy, 3) electrodessication, tissue destruction by heat, or 4) cryosurgery, tissue
destruction by freezing, used for early skin cancer. For melanoma, the primary growth must be adequately excised, and it may be necessary to remove
nearby lymph nodes. Chemotherapy has also been used, and in rare instances, complete responses do occur, but on the whole chemotherapy has failed to
improve overall survival. Surgery remains the treatment of choice for primary cutaneous melanoma. Radiation, chemotherapy, and immunotherapy are
generally reserved for the treatment of patients with metastatic melanoma or those with a poor prognosis, as an adjuvant to surgery. When reviewing
SLMC melanoma cases, we noticed a decrease in the number of cases treated with radical excision in 1994 when compared to 1989, but an increase in
the number of cases where surgery and adjuvant therapy was given.
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IMMUNOTHERAPY

AS TREATMENT FOR METASTATIC

MELANOMA

Therese M. Mikolajczak, RN, BSN
Immunotheraphy Program
Coordinator

Patients diagnosed with metastatic melanoma, Stage IV,
have an average life expectancy of 6 to 8 months.
Conventional treatment, including radiation and
chemotherapy, is most often ineffective. Current efforts in
treatment of metastatic melanoma have focused on the
use of biologic response modifiers to stimulate the host
immune system to attack tumor cells. While this approach
is still in its infancy, initial results show some promise in
enhancing therapeutic benefits for patients.
Immunologic approaches to the treatment of melanoma
seem promising due to demonstrated immunogenicity of
melanoma cancer cells. A unique interaction between the
immune system and melanoma cells has been documented
both invitro and invivo. Also, the rare occurrence of
spontaneous regression of melanoma provides evidence
that an immune response is capable of eradicating tumor.
These factors and others have led to widespread research
in manipulating the immune system as effective therapy
and perhaps prevention of melanoma.
Immunotherapy is classified as specific or non-specific,
based on whether treatment is targeted directly to the
tumor (specific), or generalized enhancement of the
immune response (non-specific). The classifications can be
subclassified as active and passive immunotherapy. Active
therapy involves stimulation of the host to generate a
desired immune response. Passive immunotherapy, also
referred to as adoptive immunotherapy, requires actual
administration of a desired effector agent to the patient,
such as an antibody or T-cell, which was manipulated
ex-vivo to produce a very selective immune response.
A wide range of investigational immunotherapy agents
have been utilized in clinical trials for metastatic
melanoma. Included are tumor vaccines, recombinate

produced cytokine including Interleukin-2 and Interferon,
monoclonal antibodies and cellular therapy with lymphokine activated killer cells, and tumor infiltrating lymphocytes. As clinical trials continue to develop, a tendency for
investigators to use multiple forms of immunotherapy to
elicit a more potent and durable response has been seen.
Results from these clinical trials are mixed, with reports
generally showing a 20% to 30% response.
Additional attempts made to optimize the effects of
immunotherapy agents have been made by adding
standard chemotherapy to the regimen. Combination
chemotherapy/immunotherapy have demonstrated a
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slightly more promising response rate, with the highest
being 57%. Unfortunately, clinical cures remain rare, and
the treatments have not been effective against central
nervous system metastases.
Though response rates are modest, progress has been
made in the treatment of metastatic melanoma utilizing
immunotherapy. The future must be directed toward
physicians, nurses, immunologists, and molecular
biologists to understand the immune mechanisms that
some patients clearly exhibit for killing melanoma, and
packaging these mechanisms for use in other patients with
melanoma, as well as other cancers.
A

Therese M. Mikolajczak, RN, BSN

5 YEAR SURVIVAL FOR MELANOMA
PATIENTS (15 PATIENTS DIAGNOSED IN 1989)
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According to the American Cancer Society, there has been a marked
increase in S year survival for melanoma. In the 1940’s, five year
survival was at 40% and now it is approximately 80%. Since the
effectiveness of the principal treatment modality (surgery) has not
changed substantially over the past several decades, the improved 5 year
survival may be attributed to earlier detection. However, despite
improved survival rates, the death rate continues to climb due to an
exponentially increasing incidence rate. SEER published 5 year survival
rates are as follows: Local = 92.1%, Regional = 54.6%, Distant =
14.2%, and unknown stage = 61.2%. For all cases it is stated to be
84.1%. These S year survival rates by General Summary Stage are for
cases diagnosed during 1983-87, and are based on follow-up of the
patients though 1990, as reported by SEER. When the survival rates of
the 15 SLMC melanoma patients from 1989 are reviewed (see above),
they appear lower than those published by SEER.

MOLECULAR GENETIC ANALYSIS OF HUMAN
MELANOMA ANTIGEN GENES

Martin K. Oaks, Ph.D
Immunology Research Lab

J

*

There are approximately 32,000 new cases of cutaneous
malignant melanoma diagnosed annually in the United
States alone and 7,800 melanoma-related deaths. The U.S.
incidence rates for malignant melanoma have been
increasing more rapidly than for any other cancer except
that of the lung. These frightening statistics have spawned
increased attention to the development of alternative
therapies. Evidence that a more favorable prognosis is
associated with a greater magnitude of T-lymphocyte
infiltration in the tumor, has made melanoma an
attractive candidate for immunotherapy trials. The other
finding that makes melanoma a good candidate for
immunotherapy is the fact that the antigens expressed on
melanoma cells are the most well characterized of any
other tumor type. One of the types of antigens expressed
on many melanomas are referred to as MAGE (Melanoma
antigen nes), and the MAGE antigens are being used
as targets for immunotherapy in a number of clinical trials
in both the U.S. and Europe. As part of the
immunotherapy protocols for treatment of melanoma at
St. Luke’s Medical Center, including tumor infiltrating
lymphocyte (TIL) therapy and the use of a therapeutic
melanoma vaccine, Dr. John P. Hansen and my lab began
a basic research project designed to examine the
relationship between MAGE expression on tumor cells
and clinical response to immunotherapy.

Our findings have important implications for the design
and implementation of immunotherapy protocols directed
at the MAGE antigens. This is because each cell in our
bodies (and thus each tumor cell in melanoma) only has a
single active X chromosome. By contrast, each cell has
two copies of other chromosomes. The fact that only one
active copy of the X chromosome is present in melanomas
makes it more likely that a tumor can spontaneously lose
MAGE expression, thereby becoming resistant to MAGE
directed immunotherapy. The practical importance of our
findings is that we recommend that patients on such
immunotherapy protocols be monitored periodically to
ensure that the tumor does not develop relapse because of
the loss of MAGE expression. ‘
Acknowledgement: This work was supported by Grant
225-8 from the Vince Lombardi Cancer Clinic.

Martin K. Oaks, Ph.D
Immunology Research Lab

As part of this work, we attempted to make a “genetic
map” of the three known MAGE genes. To this end, we
used molecular biology techniques to show that the
MAGE family of genes are all located on the human X
chromosome. We also showed that the genes are very
closely linked towards the very end or “tip” of the X
chromosome. In other words, the MAGE genes are
physically very close to each other on the X chromosome.
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PROTECTING YOURSELF AGAINST SKiN CANCER
A simple ABCD rule that outlines the warning signals for
melanoma is shown in the chart. As a general rule, any
change in an existing mole or growth or the appearance of
new growths should be evaluated by your physician.
Carol A. Rausch, RN
Cancer Outreach Coordinator
I

According to the American Cancer Society, more than
700,000 people will be diagnosed with skin cancer in the
United States this year, making it the most common form
of cancer. The good news is that most of these 700,000
skin cancers are the two most curable types: basal cell and
squamous cell cancers. Over 33,000 people, however, will
be diagnosed with melanoFa, a potentially deadly skin
cancer. Fortunately, when it’s detected early, skin cancer
is one of the most curable forms of cancer. Better still,
most skin cancer can be prevented.
Overexposure to the invisible ultraviolet (UV) rays of the
sun is the major cause of skin cancer. Sunlamps and
tanning booths are also harmful, since they also produce
UV rays that damage skin cells. Anyone can develop skin
cancer, but those with fair complexion, red or blond hair,
and who sunburn easily, are most prone. Other less
significant risk factors include occupational exposure to
chemical compounds such as coal and arsenic, and a
family history of skin cancer.
Prevention is often a matter of good habits and common
sense. The best defense against skin cancer is protection
from the sun and ultraviolet light. Unprotected skin can
burn in just 12 minutes, so avoid being out in the sun
between 10 am and 3 pm, when the harmful rays are
strongest. Wear protective clothing, such as a
widebrimmed hat, long-sleeved shirt and pants. Use
sunscreen! Choose one with a Sun Protective Factor (SPF)
of 15 or higher. Sunscreen should be reapplied after
swimming or exercise because water and perspiration may
wash off the sunscreen. Precautions should be taken on
cloudy days as well, since many harmful rays sneak
through clouds and haze. Above all, protect children!
Greater than 90% of skin damage from sun exposure
occurs before the age of 20. Also, there is a possible link
between severe sunburns in childhood and an increased
risk of melanoma later in life. Infants less than one year of
age should be shaded from the sun completely.
Early detection of skin cancer is critical. Adults should
perform periodic skin self-examination (SSE). The
American Cancer Society recommends SSE once a month.
Knowing your skin makes finding an early skin cancer
easier. Basal and squamous cell skin cancers may appear
as a pale, waxlike, pearly nodule, or a red, scaly, sharply
outlined patch. Melanomas often start as small mole-like
growths that change in size, shape color or begin to bleed.
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Carol A. Rausch, RN

The ABCD’s of Melanoma
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Asymmetry- One half
doesn’t match the
other half.

Border irregularity- The
edges are ragged, notched
or blurred.

Color- The pigmentation
is not uniform. Shades of
tan, brown and black are
present. Dashes of red,
white and blue add to
the mottled appearance.

Diameter- Greater than
six millimeters (about the
size of a pencil eraser).
Any growth of a mole
should be of concern.

OCULAR MELANOMAS

William J. Pao, MD
Radiation Oncology

Eye

Ocular Melanomas are rare malignancies of the
pigmented layer of the retina. Although only 2000 cases
are diagnosed a year, they are the most common primary
intra-ocular malignancies in adults.
In the past, enucleation was the treatment of choice, but
with the advent of modern therapies, it is possible for
patients to be cured ci keep their vision. In addition,
there has been much speculation and many retrospective
studies that show enucleation increases the risk of distant
metastasis (to the liver) in these patients.
The diagnosis of the tumor is often made by direct
ophthalmoscopic exam. It often mimics retinal
detachment. Fluorescein angiography is often used since
the tumors are highly vascular. Biopsy is seldom obtained
due to the risk of retinal damage. The alternatives to
enucleation include: photocoagulation, cryotherapy, and
high energy ion beam and radioactive implant with an
episcieral eye plaque.

.

.

Plaque

Tumor

.

EYE

Lens

Figure 1

Technically, tumors that are less than 15 millimeters in
diameter, and are at least one disc diameter from the optic
nerve, are suitable for eye plaque implantation.
Since 1993, we have developed a system for eye plaques at
St. Luke’s Medical Center. This procedure is done in the
operating room with ophthalmology. The eye plaque is
sutured over the sclera portion overlying the tumor (see
Figure 1 ) for a period of time, usually 3 to 5 days. For
radiation safety reasons we have elected to use Iodine
125, which minimizes exposure to personnel, but can
deliver a dose of 10,000 to 20,000 cGy to the apex of the
tumor.
In properly selected cases, the local control rate should be
80-90%. About 10-20% of patients will develop distant
metastases. Patients are seen every 3-4 months for the first
several years by ophthalmology and radiation oncology.
Direct exam and CT/MRI (see Figure 2) is often used for
follow-up. By properly selecting patients, we offer them a
chance for visual preservation in this disease.
MRI scan of 1-125 eye plaque overlying an ocular melanoma.

Figure 2
William J. Pao, MD
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COMMUNITY EDUCATION ABOUT SKiN CANCER

Kathy Griebenow
VLCC Hotline Assistant

The St. Luke’s Medical Center Cancer Program sponsored
a community lecture “Skin Cancer: The Great Cover-Up”
on May 31, 1995. Three dermatologists on staff presented
information on skin cancer prevention and early detection
in response to a recognized need of the community to be
aware of the dangers of intentional and passive sun
exposure and its direct relationship to skin cancer.
The importance of early detection and intervention in the
successful treatment of skin cancer was highlighted with a
focus on the different kinds of skin cancer, the most

common interventions and procedures and the success
rates for each type. Malignant Melanoma was discussed
with particular attention on prevention and the use of sun
screen and proper attire whenever participating in any
activities in the sunlight.
Subsequent educational efforts after the lecture were
provided. Articles were written for the “Vince Lombardi
Cancer Clinic Update,” a publication of primary care
physicians, and for the “Freedom 55/65 News,” a
publication for members of the Freedom 55/65 program.
Vince Lombardi Cancer Clinic Skin Self Exam shower
cards and sun screen were distributed to the participants
at the malor health fair events thr’oughout spring and
summer.

Kathy Griebenow
VLCC Hotline Assistant

COMMUNITY EDUCATION: VINCE LOMBARDI
LECTURESHIP SERIES
January 20, 1994

Prostate Cancer
Information for the General Public
St. Luke’s Medical Center

February 24, 1994

Breast Cancer
Information for the General Public
New Berlin Health Care Center

March 22, 1994

Psycho-social Aspects of Cancer
Information for the General Public
Whitefish Bay Women’s Club

May 4, 1994

Sexuality and Relationship Recovery After Cancer Treatment
Information for patients and their significant others
St. Luke’s Medical Center
Schroeder Fellowship Program

September 27, 1994

Prostate Cancer Annual Symposium
The Grand Milwaukee Hotel
“Early Detection for Prostate Cancer: Benefits and Pitfalls”
Stuart W. Fine, MD
Jeffrey A. Derus, MD
Samuel J. Otto, MD
Elliott Silbar, MD
Mark Waples, MD
Barry H. Usow, MD

October 3, 1994

“Cancer... There’s Hope”
Annette and Richard Bloch
Information for cancer survivors, friends and families
St. Luke’s Medical Center
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VINCE LOMBARDI CANCER CLINIC UPDATE

Patty Abella, RN
Manager VLCC

c

Caring with a commitment to excellence is exemplified in
every staff interaction with patients and their loved ones
in the Vince Lombardi Cancer Clinic (VLCC). The VLCC
team is committed to collaboration, with the goal being to
meet the needs of the patients while maintaining their
quality of life. The team is comprised of medical
oncologists/hematologists, registered nurses, clinical nurse
specialists, oncology technicians, social workers,
pharmacists, a dietician, a chaplain, and secretaries who
serve patients and callers through the use of the Vince
Lombardi hotline.
The Vince Lombardi Cancer Clinic continues to support
the Autologous Bone Marrow Reinfusion and Immuno
therapy programs. These programs are expanding and
participating in research to facilitate improved quality of
life and survival of patients with multiple cancer
diagnoses.

The P1CC service (peripherally inserted central catheter) is
a new program which was offered to patients in December
of 1994. The program is a joint venture between the
Diagnostic and Treatment Center and the Vince Lombardi
Cancer Clinic. Specially trained nurses from these areas are
available to place P1CC lines for both inpatients and
outpatients. The P1CC program was developed to meet the
need for patients to have easier and more comfortable
access to their veins for IV therapies which lasted greater
than seven days and less than one year.
Research studies are ongoing as to how to improve the
quality of life and spiritual outcomes of patients. The
Pastoral Care Department is inthe process of a two year
research project made possible through a grant from the
Vince Lombardi Research Advisory Committee.
The Vince Lombardi Cancer Clinic continues to proudly
provide state of the art, comprehensive care for persons
with oncologic and hematologic diagnoses.
Patty Abella, RN
Manager VLCC
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OPERA STAR, JOSE CARRERAS, VISITS
ST. LUKE’S MEDICAL CENTER

Marija Bjegovich, RN, MSN
Director of Cancer Services

Immunotherapy, Bone Marrow Transplantation, and
Genetic Engineering in order to develop more effective
treatments for patients with cancer. Clinical trials are
currently underway for melanoma, multiple myeloma,
renal, breast, ovarian, and refractory cancers.

Marija Bjegovich, RN, MSN

Opera star, Jose Carreras, who is a cancer survivor,
visited the St. Luke’s Medical Center Immunotherapy
Research and Treatment Institute on June 5, 1995 along
with the press to discuss the important role cancer
research has played in his life. He is pictured (center)
talking with John P. Hanson, MD, Medical Director of St.
Luke’s Immunotherapy Program (right), and William G.
Schuett, Sr., president and CEO of Security Bank, a major
benefactor of the Immunotherapy Program. Dr. Hanson
gave Maestro Carreras and the press a brief overview of
the cancer research being done at St. Luke’s. The focus of
the Immunotherapy Research and Treatment Institute is
to combine clinical and translational research elements of

L

-

William G. Schuett, Sr.
Maestro Jose Carreras
I ohn P. Hanson5 MD
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SPIRITUAL CORNER
Spiritual Well-Being and Hope in Cancer Patients

I

Marcia Marino
Chaplaincy Services

c

The Pastoral Care Department offers spiritual and
emotional support to patients and families who are
dealing with cancer. Chaplains offer pastoral care services
to both inpatients and outpatients. They provide spiritual
resources (including sacraments) as requested by the
patient and help to facilitate contact with the patient’s
own congregation. The Pastoral Care staff is composed of
chaplains of many faith groups. Chaplains are available in
the hospital 24 hours daily.
Chaplains also offer spiritual and emotional support to
Cancer Center staff. Support is offered through workshops, informal individual meetings, and an annual staff
retreat.
The Pastoral Care Department received funds in 1994
from the Vince Lombardi Research Foundation for three
research projects:

This study focuses on spiritual well-being and hope in
hospitalized and outpatient cancer patients. It will compare
the level of spiritual well-being with the level of hope in these
patients. It will also study whether hospitalization status
(i.e., inpatient versus outpatient) is correlated to spiritual
well-being and hope in cancer patients. The research tools
that are being used for the study are the Miller Hope Scale
and the JAREL Spiritual Well-Being Scale.
Does Structured Instruction Influence Cancer Attitudes
and Beliefs?
A

This study will compare the cancer attitudes and beliefs of
St. Luke’s Clinical Pastoral Education students with those
of area seminary students. The Cancer Attitude Questionnaire is the research tool which is being used in the study.
A Survey of the Role of the Chaplain with Oncology and
Cardiology Patients

This study will use a survey to assess the specific needs of
patients for chaplaincy services. The survey is being sent
to recently discharged patients, spouses and significant
others, and area pastoral ministers.
Marcia Marino
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SUPPORT GROUPS
For people whose 1ivs have been touched by cancer
to provide education, a sharing of experiences, and
inspiration.

...

Your Caring Connection
For patients experiencing cancer, their families and
friends. Meets the second and fourth Monday of each
month from 6:30 8:00 p.m. at St. Luke’s Medical
Center. For more information, call the Vince Lombardi
Cancer Hotline at 649-7200.
-

Make Today Count
For people with cancer or other life-threatening illnesses
and their families, sponsored by St. Luke’s Medical
Center. Meets the fourth Thursday of each month from
7:30 9:00 p.m. at Cudahy United Methodist Church,
5865 South Lake Drive. For more information, call Kerry
Twite, CNS, at 649-6000 or the Vince Lombardi Cancer
Hotline at 649-7200.
-

Ovarian Cancer Awareness Group
For women who are at risk for, or who have been
diagnosed with ovarian cancer. Meets on the first Tuesday
of every month from 6:30 8:00 p.m. at St. Luke’s
Medical Center. For more information, please call
Jeannette Wade, at 649-6000 or the Vince Lombardi
Cancer Hotline at 649-7200.
-

Kid’s Connection
To help children ages S through 1 8 cope when a parent or
loved one has cancer. Meets for 4 weekly sessions at St.
Luke’s Medical Center. Registration is required. This group
is offered periodically. For dates/times of next group, call
the Vince Lombardi Cancer Hotline at 649-7200.
The Breast Cancer Support Group
For women who have been diagnosed with breast cancer,
their families and friends. Meets the last Tuesday of the
month at 6:00 8:00 p.m. at St. Luke’s Medical Center. For
more information call Kathy Schroeder, Breast Care
Coordinator at 649-6000 or the Vince Lombardi Cancer
Hotline at 649-7200.
The ABMT Support Group
For persons who have undergone an autologous bone
marrow transplant (ABMT). For information about dates
and times call Pam Lyon, ABMT Coordinator at 649-6000
or the Vince Lombardi Cancer Hotline at 649-7200.
For more information on these and other support groups
available at St. Luke’s Medical Center, please call Pastoral
Care, 649-6567 or the Vince Lombardi Cancer Hotline at
649-7200.
There is no charge to attend these support groups.
Patients and families may attend as many sessions as they
wish.
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FORMATION OF PROSTATE CANCER SUPPORT GROUP
NETWORK
.

In December of 1994, one hundred and twenty-five men
attended an organizational meeting to develop a support
network for men diagnosed with prostate cancer.
The prostate cancer support groups were formed from.
this initial meeting. The prostate cancer support group
offers men a time to gather together for inspiration,
information, education, and camaraderie.
There are many different treatments for prostate cancer
and men need information about these options so they
can make decisions that are best for them. The prostate
cancer support group provides information about prostate
cancer and the latest treatment options. The group offers
men the opportunity to openly discuss their concerns
about treatment choices to assist in the patient’s decisionmaking process.
The meetings provide emotional support to men recently
diagnosed, those undergoing treatment and those who
have completed their treatment. It affords men the
opportunity to share experiences and feelings in an
atmosphere of respect and sensitivity. Time is set aside to
talk about coping, adjusting, and problem-solving.

Kerry Twite, RN, MSN, CNS

V’4

,

A

Gene Leffingwell, Pastoral Care

Special presentations are held throughout the year. At
these meetings, information is provided by specialists in
the various fields related to prostate cancer, such as
radiation, surgery, nutrition, and psychology.
Prostate cancer support groups are held in four locations
in the Milwaukee area:
First Wednesday of the Month, 10:00 am
Newtowne Medical Group North Shore
$706 North Port Washington Road, Fox Point
-

First Wednesday of the Month, 7:00 pm
St. Luke’s New Berlin Health Care Center
14555 W. National Avenue, New Berlin
First Thursday of the Month, 1:00 pm
St. Luke’s Medical Center
2900 West Oklahoma Avenue, Milwaukee
First Thursday of the Month, 7:00 pm
St. Luke’s Medical Center
2900 West Oklahoma Avenue, Milwaukee

Kerry Twite, RN, MSN, CNS
Gene Leffingwell
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CANCER REGISTRY ANNUAL REPORT STATISTICS
In 1994, the Cancer Registry at St. Luke’s Medical Center
accessioned 1,585 new cases: 1,399 analytic and 186 nonanalytic. The five most common cancer sites in 1994 were
breast, skin, lung, prostate and colon. According to
Cancer Facts & Figures 1994 estimates for Wisconsin
and the United States predicted prostate cancer to be the
most common cancer to be diagnosed in 1994, with
breast cancer being second. (Cancer Facts & Figures do
not include basal cell or squamous cell carcinomas of the
skin). At St. Luke’s, females accounted for slightly more
than half of the new cases (51.4%) with males accounting
for 48.6%. A majority of the new patients (1,146 or
72.3%) were between the ages of 50 and 79.
Adenocarcinoma was the most frequent histology
diagnosed, followed by infiltrating duct cell carcinoma,
squamous cell carcinoma and basal cell carcinoma.
-

In 1994, the Cancer Committee at St. Luke’s Medical
Center petitioned the Commission on Cancer to approve
changing the Cancer Registry reference date to January 1,
1985. The request was granted. In accordance with the
Commission on Cancer, the registry ceased follow-up of
the patients entered into the registry prior to 1985. The
cases prior to 1985 would be available for data requests
with the exception of survival studies. Also in 1994, it
was decided to follow the recommendation of the
Commission on Cancer and discontinue the follow-up of
localized basal cell and squamous cell carcinomas of the
skin and cervical carcinoma in-situ.

Throughout 1994, the Cancer Registry supplied 24
requests for data to physicians, administrative staff, and•
other requestors for purposes such as research, surveys,
and marketing. We also participated in the Patient Care
Evaluation studies for larynx and hypopharynx cancer
obtained through the American College of Surgeons. In
addition, Cancer Committee initiated internal studies on
survival for Autologous Bone Marrow Transplant patients
and on Anal Cancer. The Cancer Registry has appreciated
the opportunity to supply the needed data to our
requestors and we look forward to the continued use of
our data throughout the hospital.

The graphs and charts throughott this 1994 Cancer
Program Report represent a small overview of cancer
diagnosis and treatment at St. Luke’s Medical Center. A
focus on skin cancer cases, separating melanoma and nonmelanoma malignancies, has been included in this year’s
report. Comparisons with state and national figures, as
well as narratives, have been furnished when available.
For further information, please direct requests to the
Cancer Registry staff at 649-6720.

Sandy Blixt, RRA
Cancer Registry Coordinator

In 1994, the Cancer Registry data base included
information on approximately 23,000 cancer cases,
approximately 6,000 of which are followed on an annual
basis. With the assistance of physicians, office staff, area
hospitals and area Cancer Registries, we maintained a
98% successful follow-up rate. The remaining 2%,
considered lost to follow-up, were well within the 10%
allowed by the American College of Surgeons.
The following is a comparison of national and state estimates for cancer diagnosis in 1994 and the actual 1994 figures for St. Luke’s Medical Center
(SLMC). (Estimated figures for Wisconsin and the U.S. were taken from Cancer Facts & Figures 1994) The table reveals a higher than estimated
number of cases for both breast and lung cancer when compared to state and national numbers. SLMC also has a lower than expected distribution of
prostate and colorectal cases than estimated for both Wisconsin and the United States.
-

1994 U.S.A.

1994 WISCONSIN

1994 SLMC

(ESTIMATED NO. OF
CASES) (1,208,000)

(ESTIMATED NO. OF
CASES) (24,000)

(ACTUAL NO. OF
CASES) (1,585)

BREAST

183,000(15.1%)

3,700(15.4%)

260(16.4%)

LUNG

172,000 (14.2%)

2,800 (11.7%)

214 (13.5%)

PROSTATE

200,000 (16.6%)

4,700 (19.6%)

164 (10.3%)

COLORECTAL

149,000 (12.3%)

3,000 (12.5%)

178 (11.2%)

SITES

24

-

-

-

SITE DISIRifiUTION 1994
-

NUMBER OF CASES

SITE DISTRIBUTION

MALES

FEMALES

TOTAL

1

259

260

131

$5

216

125

89

214

Prostate

164

0

164

Colon

57

56

113

Rectum, Rectosigmoid Junction, & Anus

35

30

65

Ureter/Bladder

35

18

53

Hematopoietic System

26

23

49

Kidney, Renal Pelvis, & other Urinary

34

13

47

Pancreas

17

25

42

Endometrium

0

39

39

LymphNodes

13

19

32

Unknown & Ill-defined

16

16

32

Brain, CNS, Peripheral Nerves

16

16

32

Cervix

0

30

30

Lips, Oral Cavity, Pharynx

14

11

25

SoftTissue

9

16

25

Ovary & Unspecified Female Genitalia

0

23

23

Stomach

14

7

21

Esophagus

13

4

17

Larynx

12

2

14

Liver, Gallbladder, Bile Ducts

5

9

14

Thymus, Heart, Mediastinum

8

3

11

Thyroid

3

6

9

Male Genitalia

9

0

9

Female Genitalia (Vulval & Vagina)

0

7

7

Bone

5

2

7

Eye & Lacrimal Gland

2

3

5

Small Intestine

3

2

5

Retroperitoneum/Peritoneum

2

0

2

Accessory Sinuses

0

1

1

Nasal Cavity & Middle Ear

0

1

1

Respiratory/Intrathoracic

1

0

1

770

815

1,585

Breast

;

Skin
Bronchus & Lung

TOTAL

.

.
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CANCER REGISTRY ANNUAL REPORT STATISTICS
CLASS OF CASE AT DIAGNOSIS
Number Of Cases

Percent

12

.7%

910

57.4%

Class 1

477

30.1%

Class 2 First diagnosed elsewhere and all
or part of first course of therapy done at this facility

180

11.4%

-

1994

Class Of Cases

Analytic:

Class 0 First diagnosed at this facility
-

and all course of therapy elsewhere

First diagnosed and all or part
of first course of therapy done at this facility
-

-

Non Analytic:
Class 3 First diagnosed and all first course
-

-

of therapy elsewhere, subsequent courses
of therapy at this facility
6

.3%

Class 5 First diagnosed at autopsy, an incidental
finding of cancer at time autopsy performed
-

TOTAL

1585

GENERAL SUMMARY STAGE AT DIAGNOSIS ALL 1994 CASES
-

Distant 17.4%

__—-—Th
1994 SLMC

2vn

1993 WI

InSitu
Local

5.4%

8%

50.2%

42%

Regional

21.6%

23%

Distant

17.4%

15%

Unknown

5.4%

8%

100 %
*

1993 Wisconsin figures do not equal 100%

due to the exclusion of “Non-localized” tumors.

For most types of cancer, the extent of tumor spread at the time of initial diagnosis contributes to prognosis. Approximately 55% of all the new cancers
diagnosed at St. Luke’s Medical Center (SLMC) in I 994 were limited to the organ of origin (in-situ or local) at the time of initial diagnosis. A
comparison is made between 1994 SLMC data and 1993 state of Wisconsin data (most current figures available). In 1993, 50% of the new cancer cases
in Wisconsin were diagnosed with in-situ or local disease.

A comparison of stage at diagnosis for skin cancer (non-melanoma) is not available since the Wisconsin Cancer Reporting
System excludes non-melanomas of the skin from their published totals. Using the data available from Wisconsin in 1993,
and from the SEER Program, 1983-87, we note that St. Luke’s has a higher percentage of breast, lung and prostate cancer
patients diagnosed with local disease than both Wisconsin and SEER. There is a slightly lower percent of colon cancer
patients diagnosed with local stage at SLMC than at SEER. We also noted a lower percent of distant stage prostate and
colon cancer patients at SLMC when compared to both Wisconsin and SEER. Other figures vary with our facility
averaging between those of Wisconsin and SEER in some cases.

26

lop FiVE SITES FOR 1994
BRONCHUS & LUNG (214 CASES)

BREAST (260 CASES)

/
In Situ
9.6%
Unknown
2.3%
Distant
4.2%

1994 SLMC
InSitu
Local
Regional
Distant
Unknown

1993 WI

9.6%
56.2%
27.7%
4.2%
2.3%

1983

-

Unknown

1994 SLMC

87 SEER
.
,

55%
27%
4%

Local 25.2%

53%
36%
7%

Local
Regional
Distant
Unknown

25.2%
30.4%
40.2%
4.2%

1993 WI
22%
29.4%
36%

1983

87 SEER
16%
32%
37%
-

PROSTATE (164 CASES)

SKIN (216 CASES)

In Situ
10.2%
Distant
Unknown
0.5%
Regional
1.4%

In Situ
Local
Regional
Distant
Unknown

1994 SLMC

Percent

SLMC
22
188
3
2

Local
Regional
Distant
Unknown

10.2%
87%
1.4%
.9%
_5 ¾

79.3%
10.4%
6.7%
3.6%

1993 WI
67%
14.2%
7%

1983

-

87 SEER

58%
14%
18%

COLON (113 CASES)

InSitu
Local
Regional
Distant
Unknown

1994 SLMC

1993 WI

6.2%
33.7%
38.9%
10.6%
10.6%

31%
44%
13%

1983

-

87 SEER

In Situ
6.2%
Unknown
10.6%
Distant
10.6%

34%
40%
20%
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CANCER REGISTRY ANNUAL REPORT STATISTICS
AGE AT DIAGNOSIS BY SEX
NUMBER OF CASES
7Males
I 0 Females

0-29

30-39

26Males
41 Females

40 49

44 Males
91 Females

-

50-59

B 7 Males
— 10 Females
Males
Females

26 Males
41 Females

—

.

—

=
=

44 Males
91 Females

lOOMales
123 Females

100 Males
123 Females
A

60

70

80

-

-

-

69

232 Males
204 Females

79

267 Males
220 Females

89

84 Males
106 Females
10 Males
20 Females

90+

232 Males
204 Females

267 Males
220 Females

84 Males
106 Females

10 Males
20 Females

.

I

1,585

0

I _I_

I

I

I

10 20 30 40 50 60 70 80 90 100110 120 130 140 150 160 170 180 190200210220230240250260270280290300
NUMBER OF PATIENTS

15 MOST FREQUENT HISTOLOGIES 1994

AGE AT DIAGNOSIS
SLMC (1994) vs. STATE OF WISCONSIN (1993)

-

2$

Histology Distribution
Adenocarcinoma
Infiltrating Duct Cell Carcinoma
Squamous Cell Carcinoma
Basal Cell Carcinoma
Epithelial Tumor/Carcinoma
Large Cell Carcinoma
Small Cell Carcinoma
Renal Cell Carcinoma
Papillary Transitional Cell Carcinoma
Lobular Carcinoma
Squamous Cell Carcinoma In Situ
Melanoma/Pigment Nevus
Papillary Adenocarcinoma
Intraductal Carcinoma, Non-infiltrating
Multiple Myeloma
All Others (124 with counts not displayed)

409
I 74
139
119
$2
27
27
27
25
24
20
20
19
19
19
435

TOTAL

1,5$5

45%
5,,

40%

5’,
35/0

U
m

0

U 25%
20%
U

15%
10%
5%
0
AGE
AGE
0 29
30 39
40 49
50 59
60 69
70 79
80+
-

-

-

-

-

-

SLMC
1.1%
4.3%
8.5%
14.1%
27.5%
30.7%
13.9%

3.2%
4.3%
7.5%
12.1%
24.8%
30.2%
18.0%

TUMOR BOARD CONFERENCES
General Tumor Conférences are held on the first, second,
and fourth Mondays of every month at noon. On the
third Monday of the month, a Head and Neck Tumor
Conference is held. Cases are selected by a physician and
a pathologist who act as co-moderators for the
conference. The Cancer Registry contacts Laboratory
Medicine, Radiology, and Nuclear Medicine and requests
the slides and films necessary for each case presentation.
The registry then creates a summary of each patient s
work-up and diagnosis to date for distribution at the
conference. All physicians involved in the cases are invited
to attend. Each conference provides an opportunity for
interdisciplinary discussion of treatment options while
serving as an educational tool for residents, medical
students and hospital employees. The conferences have an
average attendance of 40 health care providers. Attendees
include physicians, residents, students, nurses, pharmacy,
support staff and other allied health professionals. For
more information regarding the Tumor Conferences, or to
make arrangements to have a case presented, please call
649-6720.
.
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Tumor Conference Review of Cancer Sites
Site
No. of Cases
Oral Cavity
17
Breast
13
Lympnoma
9
Colon
2
Pancreas
7
Itidne y
7
Lung
6
Sarcoma
6
Esopnagus
4
Enuometnum
4
‘
Rectum
4
B rain/CNS
4
Melanoma
3
Bladder
2
HoagKin 5 Disease
2
UnKnown Primary
2
u reter
2
Thyroid
2
Testis
2
Ovary
2
Mesothelioma
2
Myeloma
2
Prostate
1
Leukemia
1
Histiocytoma
1
Common Bile Duct
1
Cervix
1
Plasmacytoma
1
Small Intestine
1
Thymus
1
Liver
1
Uterus
1
-

•

.

,
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St LUKE’S CANCER CONFERENCES
J anuary 26,

1994

Colorectal Cancer Screening
Michael Schmalz, MD
Primary Care Lecture

March 23, 1994

An Update on Prostate Cancer
Jeffrey A. Derus, MD
Primary Care Lecture

March 31, 1994

Chronic Lymphocytic Leukemia in the 1990’s An Update
Kenneth Foon, MD
Grand Rounds

April 14, 1994

Thyroid Neoplasms
Dr. David Yuille
Nuclear Medicine Conference

May 5, 1994

Sexuality After Cancer Treatment
Sarah Auchincloss, MD
Grand Rounds Schroeder Fellowship Program

-

A

-

June 4, 1994

Cryosurgery Presentation
Surgical Oncology Presentation
Schroeder Fellowship Program

June 9, 1994

Variation In The Treatment of Early Stage Breast Cancer
Ann Nattinger, MD
Grand Rounds

October 13, 1994

Immune Reconstitution Following BMT
Grand Rounds Schroeder Fellowship Program
-

November 5, 1994

The Second Annual St. Luke’s Schroeder Cancer Conference
For Physicians
Sponsored by the Schroeder Fellows Program in Clinical Oncology
“Post Menopausal Bleeding and Endometrial Cancer”
Larry Copeland, MD, Columbus, OH
Professor of Obstetrics and Gynecology
Director of Gynecologic Oncology
Ohio State University
“Indications For Breast Conservation From A Surgical Standpoint”
Barbara Fowbie, MD, Philadelphia, PA
Fox Chase Cancer Center
Department of Radiation Oncology
“Management of Thyroid Cancer”
Ernest Mazzaferri, MD, Columbus, OH
Professor and Chairman, Department of Internal Medicine
Professor of Physiology
Ohio State University
“Laparoscopic Surgery For Colon Cancer”
Karl Zucker, MD, Albuquerque, NM
Professor of Surgery
University of New Mexico Medical Center
Department Surgery

December 21, 1994

Transrectal Ultrasound Placement of Seeds For Prostate
Carcinoma
Peter Grimm, DO
Clinical Professor
College of Medicine of the Pacific
Northwestern Tumor Institute
Schroeder Fellowship Lecture
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GLOSSARY
Analytic Cases: Cases ‘rhich are first diagnosed and/or
given their first course of treatment at St. Luke’s Medical
Center.

Melanin: The pigment of the skin, the amount of this
substance accounts for variations in skin color in different
people and different races.

Basal Cell Carcinoma: A type of skin cancer that begins in
the basal cells of the epidermis.

Melanocytes: The cells that form and contain a pigment
called melanin.

Biopsy: A procedure where a piece of tissue or fluid (a
group of cells) is taken from a person’s body and
examined with a microscope to see if the cells are normal
or not.

Melanoma: Cancer that begins in the melanocytes.
Melanoma usually starts in the skin, often in a dark mole.
Unlike the common skin cancers, melanoma tends to
spread to internal organs.

BRM: (Biological Response Modifier) Any agent that
boosts the body’s immune system by stimulating it,
modifying it or restoring it.

Metastasis: The spread of cancer from its original site to
distant areas. The cancer cells are carried to distant sites
by blood and lymph.

Carcinoma: A type of cancer that begins in the lining or
covering tissues of an organ.

Non-Analytical: Cases which are seen at St. Luke’s
Medical Center after the first Course of treatment.

Clinical Trials: Studies designed to evaluate promising
new treatments by helping researchers learn which
approaches are more effective than others.

Regional Stage: A tumor that has extended beyond the
limits of the organ of origin into 1 ) surrounding organs or
tissues by direct extension, 2) regional lymph nodes by
metastasis, or 3) a combination of 1 and 2 and appears to
have spread no further.

Cryosurgery: The application of liquid nitrogen to a
growth to freeze and kill the abnormal cells.
Curette: An instrument with a sharp, spoonshaped end.

Recurrence: The return of cancer after a disease-free
interval.

Curettage: The surgical “scooping out” of cancer with a
curette.

Regression: Growing smaller or disappearing. Used to
describe shrinkage or disappearance of a cancer.

Dermis: The inner layer of skin. It contains blood and
lymph vessels, hair follicles, and glands.

Risk Factors: A substance or condition that increases an
individual’s chance of getting a particular type of cancer.

Distant Stage: A neoplasm that has spread to other organs
or lymph nodes from the primary tumor.

Skin: The body’s outer covering which protects against
heat, injury and infection. It regulates body temperature
and stores water, fat, and vitamin D. It is the body’s
largest organ, weighing about 6 lbs. ft is made up of two
main layers: the epidermis and the dermis.

Electrodesiccation: An electric current used to control
bleeding and kill any cancer cells remaining around the
edge of the wound.
Epidermis: The outer layer of skin. It is mostly made up of
flat, scale-like cells called squamous cells. Under the
squamous cells are round cells called basal cells. The
deepest part of the epidermis also contains melanocytes.

Skin Graft: A piece of skin from another part of the body
used to replace the skin removed.

First Course Treatment: The tumor-directed treatments
started within the first four months after diagnosis.

Stage: A term used to describe the size and extent of
spread of the cancer.

Immunotherapy: Use of the immune system or the
products of the immune system to control, damage, or
destroy malignant cells.

Ultraviolet Radiation: Cancer-causing energy that comes
in the form of rays from the sun; also called UV radiation.

Squamous Cell Carcinoma: A type of skin cancer that
begins in the squamous cells of the epidermis.

In situ: A tumor classified microscopically as in situ, noninvasive, pre-invasive, non-infiltrating, intraductal,
intraepithelial or intraepidermal.
Kaposi’s Sarcoma: A relatively rare type of cancer that
develops on the skin of some elderly persons or those with
weak immune systems, including those with acquired
immune deficiency syndrome (AIDS).
Local Stage: Tumor restricted to the organ of origin, but
may be invasive or infiltrating within the organ of origin.
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